Drug Trial Radar · NCT07747935
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Apr 1, 2028
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- ReBio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neoadjuvant RBP-01 in patients with primary uveal melanoma.
Conditions
- Uveal Melanoma
Interventions
RBP-01Drug
Each RBP-01 dose consists of a 5 µL intravitreal injection conjugating 250 µg of sotrastaurin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety eventsTime frame: From first dose until 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.